Join
Live feed
·
PRReleasevia Quantisnow
SCYNEXIS Inc. logo

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ByQuantisnow·Wall Street's wire, on your screen.
SCYX· SCYNEXIS Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SCYX (SCYNEXIS Inc.) and more on Quantisnow.